PublicWire | Emerging Market Stock News
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
No Result
View All Result
PublicWire
No Result
View All Result

Home » Medical » Co-Diagnostics, Inc. Announces Participation in Research Project with Stanford University

Co-Diagnostics, Inc. Announces Participation in Research Project with Stanford University

by Tony Allen
April 26, 2019
in Medical, Technology
Reading Time: 2 mins read
0

CoPrimers™ used in proof of concept evaluation

SALT LAKE CITY–(BUSINESS WIRE)– Co-Diagnostics, Inc. (NASDAQ: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today that the Company’s CoPrimer™ technology is being employed to achieve the objectives of a research project conducted by the Wang Group at Stanford University.

The purpose of the study is to develop more efficient methods to detect multiple genetic mutations in the EGFR (epidermal growth factor receptor) gene, including the most frequently occurring mutations in lung cancer, within a single reaction. The investigators have been conducting research into the subject using commercially available primers for several years, the results of which have previously been published, and contacted Co-Diagnostics to utilize the Company’s technology to further improve comprehensive detection methods of mutations that are known to cause cancer. It is anticipated that the results of the current study will be compiled and published later in 2018.

Co-Diagnostics CEO Dwight Egan remarked: “We were honored that the Wang Group at Stanford University approached Co-Diagnostics and expressed interest in applying our CoPrimer technology to their endeavors to improve detection of cancer. The ability to multiplex within a single reaction, along with the heightened specificity and allowing for a massive reduction in false positives, are some of the most valuable benefits of this technology, making it ideal for cancer detection and liquid biopsy applications. The continued results of this study will help to further advance the capabilities of our technology and lay the groundwork for products to service these fast-growing markets.”

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.

Forward-Looking Statements:

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Tags: Co-DiagnosticsCODXDRNAmolecular diagnosticsRNA
Previous Post

Immudyne Acquires 51% of PDFSimpli With Proceeds From Direct Institutional Investment

Next Post

Precision Therapeutics Launches New Website

Tony Allen

Tony Allen received a bachelor’s degree in journalism from the University of South Florida in 2011, specializing in feature writing and reporting on sports and events.

Related Posts

Technology

Apple taps TSMC’s latest tech and BYD races into Japan

September 15, 2022
0
Technology

Fortress China: Xi Jinping’s plan for economic independence

September 15, 2022
0
Technology

Patreon: fight for talent makes creator economy more costly

September 15, 2022
0
Technology

Wall Street shudders after seeing US inflation data

September 14, 2022
0
Technology

After the tech sell-off: will growth investors keep the faith?

September 14, 2022
0
Technology

UK university develops device to restore sense of touch to stroke patients

September 14, 2022
0
Next Post

Precision Therapeutics Launches New Website

Please login to join discussion

Subscribe To Our Newsletter

Loading
Ad
PublicWire | Emerging Market Stock News 24/7 | Investor Relations US Stock Market

© Copyright 2022 publicwire.com

Navigate Site

  • About
  • Contact Us
  • Disclaimer
  • Watch LIVE
  • Privacy Policy
  • Terms and Services
  • Contributors

Follow Us

No Result
View All Result
  • LIVE Investor News Channel
  • Cannabis
  • Energy
  • Finance
  • General
  • Medical
  • Podcasts
  • Retail
  • Technology
  • Videos

© Copyright 2022 publicwire.com

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.